Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

APO-GABAPENTIN 400 MG

GABAPENTIN : 400 MG · DIN 02244306 · APOTEX INC

Health Canada status: MARKETED

What is APO-GABAPENTIN?

APO-GABAPENTIN 400 MG contains GABAPENTIN : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02244306, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Aug-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What else is APO-GABAPENTIN called?

The same molecule, GABAPENTIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
NeurontinLatinAustralia, Bahrain, Czechia, Iceland, Norway, Saudi Arabia
Gabapentin TevaLatinCzechia, Iceland, Norway
GAPENTINLatinAustralia, Saudi Arabia
APX-GabapentinLatinAustralia
GabacorLatinAustralia
GABANOXLatinCzechia
GRIMODINLatinCzechia
Gabapentin SandozLatinAustralia, Iceland
GASENLANLatinCzechia
GABAPENTIN-WGRLatinAustralia
GABAGAMMALatinCzechia
Gabapentin APOTEXLatinAustralia
GORDIUSLatinCzechia
GabagenLatinIceland
GabanetLatinSaudi Arabia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02244306
Brand nameAPO-GABAPENTIN
Generic / active ingredientGABAPENTIN : 400 MG
ManufacturerAPOTEX INC
Strength400 MG
Dosage formCAPSULE
Route of administrationORAL
SchedulePrescription
ATC codeN02BF01 GABAPENTIN
AHFS class28:12.92
BiosimilarNo
Health Canada statusMARKETED
Status date27-Aug-2001
Original market date2001-08-27 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02244306
DIN (unpadded, as printed on some documents)2244306
Brand nameAPO-GABAPENTIN
Active ingredient / INNGABAPENTIN : 400 MG
ATC codeN02BF01
ATC anatomical main groupN — Nervous system
ATC therapeutic subgroupN02
AHFS class28:12.92
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderAPOTEX INC

Health Canada approved product monograph (PDF)

Which pack is which?

Strength on the label400 MG
Dosage formCAPSULE
RouteORAL

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

Is GABAPENTIN in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for APO-GABAPENTIN

What can be used instead?

Other Canadian products sharing ATC code N02BF01 GABAPENTIN. 60 of 161 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
APO-GABAPENTIN100 MGCAPSULEAPOTEX INCMARKETEDDIN 02244304
APO-GABAPENTIN300 MGCAPSULEAPOTEX INCMARKETEDDIN 02244305
APO-GABAPENTIN600 MGTABLETAPOTEX INCMARKETEDDIN 02293358
APO-GABAPENTIN800 MGTABLETAPOTEX INCMARKETEDDIN 02293366
AURO-GABAPENTIN100 MGCAPSULEAURO PHARMA INCMARKETEDDIN 02321203
AURO-GABAPENTIN300 MGCAPSULEAURO PHARMA INCMARKETEDDIN 02321211
AURO-GABAPENTIN400 MGCAPSULEAURO PHARMA INCMARKETEDDIN 02321238
AURO-GABAPENTIN TABLETS600 MGTABLETAURO PHARMA INCMARKETEDDIN 02428334
AURO-GABAPENTIN TABLETS800 MGTABLETAURO PHARMA INCMARKETEDDIN 02428342
GABAPENTIN100 MGCAPSULESIVEM PHARMACEUTICALS ULCMARKETEDDIN 02246314

Who else supplies GABAPENTIN worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. GABAPENTIN appears in 555 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does GABAPENTIN cost around the world?

GABAPENTIN is listed on 16 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
United Statesacquisition6261USD███.██
Australiaex-manufacturer1354AUD███.██
Italyprezzo al pubblico (classe A)646EUR███.██
Czechiamax producer price (ex-factory)745CZK███.██
Saudi Arabiapublic1933SAR███.██
AustriaKVP (Kassenverkaufspreis)2527EUR███.██
South Africasingle exit price2626ZAR███.██
Hungaryproducer price (ex-factory)1318HUF███.██
Icelandmax wholesale716ISK███.██
Romaniamax producer price1515RON███.██
Norwaymax AUP (pharmacy retail)414NOK███.██
Greeceproducer price (ex-factory)99EUR███.██
United Arab Emiratespublic88AED███.██
United Kingdomhospital66GBP███.██
Luxembourgreimbursement55EUR███.██
Bahrainretail (max)34BHD███.██

587 pack listings across 172 brand entries and 14 price bases, refreshed 08 Sep 2026. Ranges span every GABAPENTIN pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for APO-GABAPENTIN

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02244306. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.